NextCure, Inc. Made Headway
NextCure, Inc. (NXTC:NASDAQ) rocketted at $11.93, a gain of 37.1%. On Fri, Oct 17, 2025, NXTC:NASDAQ touched a New 2-Week High of $11.93. The stock appeared on our News Catalysts scanner on Fri, Oct 17, 2025 at 02:58 AM in the 'BIOTECH' category. From Fri, Oct 03, 2025, the stock recorded 80.00% Up Days and 81.82% Green Days
About NextCure, Inc. (NXTC:NASDAQ)
NextCure Inc is a clinical-stage biopharmaceutical company committed to discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. It is focused on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. The company's product candidate, NC318, is a immunomedicine against a immunomodulatory receptor called Siglec-15, or S15.
Top 10 Gainers:
- Movella Holdings Inc. (MVLA:NASDAQ), 325%
- Rani Therapeutics Holdings, Inc. (RANI:NASDAQ), 248.27%
- Artiva Biotherapeutics, Inc. (ARTV:NASDAQ), 116.97%
- Kezar Life Sciences, Inc. (KZR:NASDAQ), 52.15%
- New Era Energy & Digital Inc Com (NUAI:NASDAQ), 44.44%
- Carbon Revolution Public Limited Company (CREV:NASDAQ), 43.36%
- VirnetX Holding Corp (VHC:NASDAQ), 40.41%
- VirnetX Holding Corporation (VHC:NYSE), 40.41%
- Latch, Inc. (LTCH:NASDAQ), 40%
- NextCure, Inc. (NXTC:NASDAQ), 37.13%